Australia Implements Strict Regulations on Nicotine Products

Oct.12.2022
Australia Implements Strict Regulations on Nicotine Products
Australia cracks down on unregulated vaping products, requiring prescriptions for nicotine products and seizing over 15,000 units worth $500,000.

As of October 2021, nicotine consumers in Australia can only purchase products containing nicotine from pharmacies with a prescription. Anyone who violates these strict regulations will face hefty fines and, in some cases, even imprisonment.


The owners of vape shops in Western Australia (WA) have recently received warnings from the WA Department of Health, instructing them to cease operations within 14 days. Additionally, 32 retailers' e-cigarettes were confiscated. A six-week health crackdown has led to the seizure of over 15,000 e-cigarettes, worth more than $500,000 throughout the state.


Meeghan Clay, Chief Pharmacist of Western Australia stated her concern regarding the high risk of developing nicotine addiction among users of e-cigarettes. Clay stated "I am extremely concerned that the majority of users who inhale nicotine will become addicted, spawning a new generation of nicotine addicts". She further noted that many manufacturers and sellers of e-cigarettes try to avoid detection, by not labeling them as containing nicotine. Consumers may not even be aware of the presence of nicotine in the product they are purchasing.


In response to this situation, electronic cigarette advocates from around the world issued a letter on Wednesday, July 20, urging the Australian Department of Health to cease its ongoing attacks on the local electronic cigarette industry.


Meanwhile, WA has recently been fined for allegedly importing and consuming nicotine products without proper authorization. His package was intercepted and seized at the border as it contained more products than the allowed limit for personal imports.


Australia's prescription model is ineffective.


Dr. Colin Mendelsohn, a tobacco harm reduction expert, has explained that Australia's prescription model for tobacco is not effective as it makes products difficult to obtain, ultimately creating a higher demand and subsequent growth in the black market.


He said, "The government has established a complex system, but it is not effective. Finding a general practitioner who can prescribe medication and then finding a pharmacy to sell it is not a feasible solution. Therefore, people resort to buying unregulated products on the black market, which is thriving and selling these products to children.


Earlier this month, Dr. Colin Mendelsohn, an Australian public health and tobacco treatment expert, launched a campaign featuring eight evidence-based videos aimed at combating misinformation about smoking in Australia. The videos are part of an effort to raise awareness and encourage smokers to quit.


Dr. Ko's Truth About E-cigarettes" is an evidence-based video campaign aimed at combating the rampant misinformation being spread by state health departments, particularly in Queensland, New South Wales, and Western Australia, regarding nicotine consumption through e-cigarettes.


Statement:


This article is compiled from third-party information and is intended for industry insiders to exchange and learn from.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The compilation of this article is solely for industry communication and research purposes.


Due to limitations in the compiler's skill level, the translated article may not fully capture the original wording. Please refer to the original article for accurate information.


2FIRSTS maintains full consistency with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.


All compiled information is copyrighted to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Russia’s Vape Device Labeling Regime Enters Force: Registration Starts in September, Mandatory Coding in December
Russia’s Vape Device Labeling Regime Enters Force: Registration Starts in September, Mandatory Coding in December
Russia's digital labeling regime for reusable e-cigarettes and similar personal vaping devices entered its first mandatory phase in September 2026. From September 1, manufacturers, importers and other market participants must register with the national Chestny ZNAK tracking system. From December 1, newly manufactured and imported covered devices will be required to carry digital identification codes and be reported as entering circulation. Russia has also issued new operational guidance for imports, marking the transition from a voluntary pilot to phased mandatory implementation.
Sep.15
Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona's First Things First is pushing for an excise tax equal to 50% of the retail price of vaping products, estimating that the measure could generate about $100 million annually. The agency says its tobacco-tax revenue has fallen 47% from 2008 levels. Arizona has attempted to broaden its nicotine tax base in each of the past two years: a 2025 bill proposed a 50% wholesale-price tax, while a 2026 measure shifted to a 50% retail-price tax covering alternative nicotine products and vapor products. Separately, the state enacted HB 4001 this year to establish a new licensing and sales framework for alternative nicotine products.
Sep.21
 PMI Opens Generative AI Center in Portugal to Support Global Operations
PMI Opens Generative AI Center in Portugal to Support Global Operations
According to information released by Portugal’s Trade & Investment Agency (AICEP) in July 2026, Philip Morris International (PMI) has established a global Generative Artificial Intelligence Factory (GenAI Factory) at its Portuguese subsidiary Tabaqueira. The center will support PMI’s global operations by developing and deploying AI solutions focused on industrial process optimization, data analytics, operational automation and AI application development. The initiative strengthens Portugal’s role in PMI’s global technology and innovation network.
Aug.27
UK Vape Maker Riot Enters Clacton By-Election to Fight Government 'White Packaging' Proposals
UK Vape Maker Riot Enters Clacton By-Election to Fight Government 'White Packaging' Proposals
British e-liquid manufacturer Riot Labs has introduced a fictional “candidate” called Riot Man around the Clacton parliamentary by-election, seeking to mobilize consumers and retailers against parts of the UK government’s proposed restrictions on vape packaging, device appearance and retail displays. Riot Man is not listed as an official candidate.
Aug.12
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands has agreed to acquire 100% of Swedish modern oral nicotine company Yoik Group AB for an initial SEK515 million, equivalent to about US$53.9 million, plus a deferred payment linked to performance over the next two years. Yoik owns nicotine pouch brand Helwit, which held about 3.4% of Sweden’s modern oral nicotine market over the past 12 months. Imperial says the acquisition will more than double its existing share of the Swedish market. Helwit is also sold elsewhere in the Nordics, through European online channels and in selected UK retail outlets.
Sep.08
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06